Abstract Search

ea0081oc4.3 | Oral Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

Long-term efficacy and safety data for oral octreotide capsules in acromegaly: mpowered trial open-label extension phase

Fleseriu Maria , Molitch Mark E , Dreval Alexander , Pokramovich Yulia G , Bondar Irina , Poteshkin Yury E , Macut Djuro P , Obermayer-Pietsch Barbara , Gilgun-Sherki Yossi , Haviv Asi , Biermasz Nienke , Melmed Shlomo , Strasburger Christian J

Background: Oral octreotide capsules (OOC) are a treatment option for patients with acromegaly in the United States. The MPOWERED trial (NCT02685709) showed that OOC were noninferior to injectable somatostatin receptor ligands (iSRLs; octreotide or lanreotide) in maintenance of biochemical control in patients previously responding to both treatments, as well as demonstrated improvements in patient-reported outcomes among patients receiving OOC.Objective:...

0 shares

ea0063p284 | Pituitary and Neuroendocrinology 1 | ECE2019

The assessment of octreotide suppression test, ihc- and mr-structure, mr-signal of gh-producing pituitary adenoma for determining the prognosis of disease and management.

Pronin Vyacheslav , Zherebchikova Kristina , Malysheva Alena , Kozhevnikov Alexander , Kalinin Pavel , Astafina Lyudmila , Rotin Daniil , Vorontsov Alexander , Ambrosimov Alexander , Grigoriev Andrei , Shishkina Lyudmila , Pronin Eugeny , Azizyan Vilen , Godkov Ivan , Belysheva Elena , Demidova Tatiana , Poteshkin Yury

Introduction: A growth hormone-secreting pituitary adenoma (GH-PA) increases the risk of complications and death. Its management is determined by MRI data and decrease of insulin-like growth factor-1 (IGF-1) during the octreotide suppression test (OST). Currently, there is evidence that MRI-T2-hypointensive somatotropinoma and high expression of somatostatin receptors type 2 (SSTR2) according to immunohistochemical analysis (IHC) predict high efficacy of somatostatin ana...

0 shares

ea0073oc13.6 | Oral Communications 13: Pituitary and Neuroendocrinology | ECE2021

A Phase 3 Large International Noninferiority Trial (MPOWERED): Assessing Maintenance of Response to Oral Octreotide Capsules in Comparison to Injectable Somatostatin Receptor Ligands

Fleseriu Maria , Dreval Alexander V. , Pokramovich Yulia , Bondar Irina , Isaeva Elena , Molitch Mark E. , Macut Djuro P. , Leonova Nina , Raverot Gerald , Grineva Elena , Poteshkin Yury E. , Gilgun-Sherki Yossi G , Ludlam William H. , Patou Gary , Haviv Asi , Gordon Murray B. , Biermasz Nienke , Melmed Shlomo K. , Strasburger Yossi G

BackgroundMPOWERED, a large phase 3 trial, assessed maintenance of response to oral octreotide capsules (OOC; MYCAPSSA) compared to injectable somatostatin receptor ligands (iSRLs) in patients with acromegaly who responded to OOC and iSRLs (octreotide or lanreotide). OOC were recently approved in the US for patients with acromegaly who responded to and tolerated iSRLs.MethodsEligibility criteria included age ...

0 shares

Endocrine Abstracts

Long-term efficacy and safety data for oral octreotide capsules in acromegaly: mpowered trial open-label extension phase

The assessment of octreotide suppression test, ihc- and mr-structure, mr-signal of gh-producing pituitary adenoma for determining the prognosis of disease and management.

A Phase 3 Large International Noninferiority Trial (MPOWERED): Assessing Maintenance of Response to Oral Octreotide Capsules in Comparison to Injectable Somatostatin Receptor Ligands

BiosciAbstracts